With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

To attract and retain workers, employers will focus on competitive salaries and flexible benefits, experts say.

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

Industry leaders share their thoughts and concerns about the health care landscape and how it will affect their 2025.

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

From GLP-1s to brand product innovation, the trend intelligence report details the overall surge of innovation and investment in women’s health technologies at the 2025 CES on Monday.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

The GLP-1s include semaglutide (Ozempic, Wegovy) and the combination of GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound).

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...